BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

752 related articles for article (PubMed ID: 30077125)

  • 1. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
    Horn L; Gettinger SN; Gordon MS; Herbst RS; Gandhi L; Felip E; Sequist LV; Spigel DR; Antonia SJ; Balmanoukian A; Cassier PA; Liu B; Kowanetz M; O'Hear C; Fassò M; Grossman W; Sandler A; Soria JC
    Eur J Cancer; 2018 Sep; 101():201-209. PubMed ID: 30077125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
    Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
    Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
    Peters S; Gettinger S; Johnson ML; Jänne PA; Garassino MC; Christoph D; Toh CK; Rizvi NA; Chaft JE; Carcereny Costa E; Patel JD; Chow LQM; Koczywas M; Ho C; Früh M; van den Heuvel M; Rothenstein J; Reck M; Paz-Ares L; Shepherd FA; Kurata T; Li Z; Qiu J; Kowanetz M; Mocci S; Shankar G; Sandler A; Felip E
    J Clin Oncol; 2017 Aug; 35(24):2781-2789. PubMed ID: 28609226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
    Rittmeyer A; Barlesi F; Waterkamp D; Park K; Ciardiello F; von Pawel J; Gadgeel SM; Hida T; Kowalski DM; Dols MC; Cortinovis DL; Leach J; Polikoff J; Barrios C; Kabbinavar F; Frontera OA; De Marinis F; Turna H; Lee JS; Ballinger M; Kowanetz M; He P; Chen DS; Sandler A; Gandara DR;
    Lancet; 2017 Jan; 389(10066):255-265. PubMed ID: 27979383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
    Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
    Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.
    Spigel DR; Chaft JE; Gettinger S; Chao BH; Dirix L; Schmid P; Chow LQM; Hicks RJ; Leon L; Fredrickson J; Kowanetz M; Sandler A; Funke R; Rizvi NA
    J Thorac Oncol; 2018 Nov; 13(11):1733-1742. PubMed ID: 29775807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
    Herbst RS; Giaccone G; de Marinis F; Reinmuth N; Vergnenegre A; Barrios CH; Morise M; Felip E; Andric Z; Geater S; Özgüroğlu M; Zou W; Sandler A; Enquist I; Komatsubara K; Deng Y; Kuriki H; Wen X; McCleland M; Mocci S; Jassem J; Spigel DR
    N Engl J Med; 2020 Oct; 383(14):1328-1339. PubMed ID: 32997907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
    Gadgeel S; Hirsch FR; Kerr K; Barlesi F; Park K; Rittmeyer A; Zou W; Bhatia N; Koeppen H; Paul SM; Shames D; Yi J; Matheny C; Ballinger M; McCleland M; Gandara DR
    Clin Lung Cancer; 2022 Jan; 23(1):21-33. PubMed ID: 34226144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
    Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
    Powles T; Durán I; van der Heijden MS; Loriot Y; Vogelzang NJ; De Giorgi U; Oudard S; Retz MM; Castellano D; Bamias A; Fléchon A; Gravis G; Hussain S; Takano T; Leng N; Kadel EE; Banchereau R; Hegde PS; Mariathasan S; Cui N; Shen X; Derleth CL; Green MC; Ravaud A
    Lancet; 2018 Feb; 391(10122):748-757. PubMed ID: 29268948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.
    McDermott DF; Sosman JA; Sznol M; Massard C; Gordon MS; Hamid O; Powderly JD; Infante JR; Fassò M; Wang YV; Zou W; Hegde PS; Fine GD; Powles T
    J Clin Oncol; 2016 Mar; 34(8):833-42. PubMed ID: 26755520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
    Emens LA; Cruz C; Eder JP; Braiteh F; Chung C; Tolaney SM; Kuter I; Nanda R; Cassier PA; Delord JP; Gordon MS; ElGabry E; Chang CW; Sarkar I; Grossman W; O'Hear C; Fassò M; Molinero L; Schmid P
    JAMA Oncol; 2019 Jan; 5(1):74-82. PubMed ID: 30242306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
    Liu SV; Camidge DR; Gettinger SN; Giaccone G; Heist RS; Hodi FS; Ready NE; Zhang W; Wallin J; Funke R; Waterkamp D; Foster P; Iizuka K; Powderly J
    Eur J Cancer; 2018 Sep; 101():114-122. PubMed ID: 30053670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
    Gulley JL; Rajan A; Spigel DR; Iannotti N; Chandler J; Wong DJL; Leach J; Edenfield WJ; Wang D; Grote HJ; Heydebreck AV; Chin K; Cuillerot JM; Kelly K
    Lancet Oncol; 2017 May; 18(5):599-610. PubMed ID: 28373005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.
    Petrylak DP; Powles T; Bellmunt J; Braiteh F; Loriot Y; Morales-Barrera R; Burris HA; Kim JW; Ding B; Kaiser C; Fassò M; O'Hear C; Vogelzang NJ
    JAMA Oncol; 2018 Apr; 4(4):537-544. PubMed ID: 29423515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung.
    Kim HS; Lee JH; Nam SJ; Ock CY; Moon JW; Yoo CW; Lee GK; Han JY
    J Thorac Oncol; 2018 May; 13(5):636-648. PubMed ID: 29378266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer.
    Chiang AC; Sequist LVD; Gilbert J; Conkling P; Thompson D; Marcoux JP; Gettinger S; Kowanetz M; Molinero L; O'Hear C; Fassò M; Lam S; Gordon MS
    Clin Lung Cancer; 2020 Sep; 21(5):455-463.e4. PubMed ID: 32586767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
    Hui R; Garon EB; Goldman JW; Leighl NB; Hellmann MD; Patnaik A; Gandhi L; Eder JP; Ahn MJ; Horn L; Felip E; Carcereny E; Rangwala R; Lubiniecki GM; Zhang J; Emancipator K; Roach C; Rizvi NA
    Ann Oncol; 2017 Apr; 28(4):874-881. PubMed ID: 28168303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    Zhang Y; Zhou H; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.